Experienced in Large-Cell Lung Carcinoma

Dr. Delphine W. Ong

Oncology
3301 C Street, Building 500, 
Sacramento, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Large-Cell Lung Carcinoma
3301 C Street, Building 500, 
Sacramento, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Delphine Ong is an Oncologist in Sacramento, California. Dr. Ong is rated as an Experienced provider by MediFind in the treatment of Large-Cell Lung Carcinoma. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Inflammatory Breast Cancer, and Classical Hodgkin Lymphoma.

Her clinical research consists of participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

3301 C Street, Building 500, Sacramento, CA 95816

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
Enrollment Status: Recruiting
Publish Date: December 05, 2025
Intervention Type: Drug
Study Drug: Screening Platform
Study Phase: Phase 2/Phase 3
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Completed
Publish Date: May 21, 2025
Intervention Type: Drug
Study Drug: Rucaparib
Study Phase: Phase 2
View 4 Less Clinical Trials
Similar Doctors
Distinguished in Large-Cell Lung Carcinoma
Dr. Jonathan W. Riess
Hematology Oncology | Hematology | Oncology
Distinguished in Large-Cell Lung Carcinoma
Dr. Jonathan W. Riess
Hematology Oncology | Hematology | Oncology

Regents Of The Univ Of Ca

4501 X St, 
Sacramento, CA 
 (1.8 miles away)
916-734-5959
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jonathan Riess is a Hematologist Oncology specialist and a Hematologist in Sacramento, California. Dr. Riess is rated as an Elite provider by MediFind in the treatment of Large-Cell Lung Carcinoma. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Thymic Epithelial Tumor, Bone Marrow Aspiration, and Gastrostomy.

Distinguished in Large-Cell Lung Carcinoma
Dr. Karen L. Kelly
Hematology Oncology | Oncology | Hematology
Distinguished in Large-Cell Lung Carcinoma
Dr. Karen L. Kelly
Hematology Oncology | Oncology | Hematology
2279 45th Street, 
Sacramento, CA 
 (1.8 miles away)
916-734-5959
Languages Spoken:
English

Karen Kelly is a Hematologist Oncology specialist and an Oncologist in Sacramento, California. Dr. Kelly is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Lung Carcinoma. Her top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Small Cell Lung Cancer (SCLC), ALK-Positive Non-Small Cell Lung Cancer, and Bone Marrow Aspiration.

Distinguished in Large-Cell Lung Carcinoma
Dr. Siao-yi Wang
Oncology
Distinguished in Large-Cell Lung Carcinoma
Dr. Siao-yi Wang
Oncology

Regents Of The Univ Of Ca

4501 X St, 
Sacramento, CA 
 (1.8 miles away)
916-734-5959
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Siao-yi Wang is an Oncologist in Sacramento, California. Dr. Wang is rated as an Advanced provider by MediFind in the treatment of Large-Cell Lung Carcinoma. His top areas of expertise are Small Cell Lung Cancer (SCLC), Large-Cell Lung Carcinoma, Lung Adenocarcinoma, EGFR Positive Lung Cancer, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ong's expertise for a condition
ConditionClose
    View All 38 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile